AIMOVIG 140 MG SOLUCIÓN INYECTABLE EN PLUMA PRECARGADA

USDailyMed:Erenumab AU:B1 N02CD01(WHO) CA:℞-only/Schedule DUS:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) 1582205-90-0 DB14039 none I5I8VB78VT D10928 ChEMBL3833329 Erenumab, sold under the brand nameAimovig, is amedicationwhich blocks thecalcitonin gene-related peptide receptor(CGRPR) for the prevention ofmigraine.It is administered bysubcutaneous injection. Erenumab, which was developed byAmgenandNovartis,was approved in May 2018, and was the first CGRPR antagonist to be approved by the U.S.Food and Drug Administration.In 2020, it was the 234th most commonly prescribed medication in the United States, with more than 1million prescriptions.